 Primary endpoint is to evaluate the Time to Recurrence with either a one instillation of 4 mg apaziquone or two instillations of 4 mg apaziquone relative to placebo instillation following TURBT in patients with non-muscle invasive bladder cancer NMIBC who receive transurethral resection bladder tumor TURBT. 